Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
about
Regular treatment with salmeterol for chronic asthma: serious adverse eventsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaCircadian rhythms in the pharmacokinetics and clinical effects of beta-agonist, theophylline, and anticholinergic medications in the treatment of nocturnal asthma.Salmeterol tachyphylaxis in steroid treated asthmatic subjects.Antagonism of long-acting beta2-adrenoceptor agonism.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.Systemic effects of salbutamol and salmeterol in patients with asthma.Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study GroupNorth of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults.Long-acting inhaled beta agonists.Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.Dose equivalence of drugs for asthma.Efficacy of inhaled budesonide and oral theophylline in asthmatic subjects.
P2860
Q24241960-91FEE078-5BD7-4301-BB44-35448CE07968Q24246441-27FBF269-A78E-4ED5-9BA9-99BC36BCFB2DQ24247926-C20EC8BB-BFEA-49F7-9132-422052389219Q33747962-B59337AB-EFE3-47F1-9AC1-24FBED37BCC5Q33775495-15D95131-8E18-4A1E-9864-5C06D438F5A7Q34866359-E8D124F2-0BB3-4DBC-984F-8DCF4BB65618Q35627925-8825CDD9-30CB-431C-8F6D-C7752C38DF81Q35980780-033C046D-9F6A-4605-8BE1-B9982CD7DBD3Q36559591-C14F530D-CAE2-42E8-9298-22303C43D0D9Q36573494-101CBF84-993A-4EF6-A844-195FCF9D0936Q36576295-6F6991C5-92E2-4321-95B3-FA12754C84A3Q36597554-B1D1F021-D678-4264-9BA2-5A5B79D2376AQ40433878-0034D2CA-0230-4238-AD60-F749B45D9036Q40713319-23D7E4D0-2161-4D80-8FCA-0282DAE6C5F2Q43433480-138325A3-FE18-46D3-92E0-9C3D09E4D2D6Q43835099-5E294995-091A-416C-AEDB-5DBEA735CDDD
P2860
Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Twelve month comparison of sal ...... atients. European Study Group.
@ast
Twelve month comparison of sal ...... atients. European Study Group.
@en
type
label
Twelve month comparison of sal ...... atients. European Study Group.
@ast
Twelve month comparison of sal ...... atients. European Study Group.
@en
prefLabel
Twelve month comparison of sal ...... atients. European Study Group.
@ast
Twelve month comparison of sal ...... atients. European Study Group.
@en
P2093
P2860
P356
P1433
P1476
Twelve month comparison of sal ...... atients. European Study Group.
@en
P2093
Lundback B
Rawlinson DW
P2860
P304
P356
10.1136/THX.48.2.148
P407
P577
1993-02-01T00:00:00Z